Quick Answer
ROCKET PHARMACEUTICALS, INC. reported Operating Income of -$231.75 million for fiscal year 2025.
ROCKET PHARMACEUTICALS, INC. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$231.75M | +15.2% |
| 2024 | -$273.20M | -5.2% |
| 2023 | -$259.66M | -15.7% |
| 2022 | -$224.34M | -34.1% |
| 2021 | -$167.25M | -24.5% |
| 2020 | -$134.30M | -76.4% |
| 2019 | -$76.15M | -7.0% |
| 2018 | -$71.16M | -259.9% |
| 2017 | -$19.77M | -161.1% |
| 2016 | -$7.57M | +62.9% |
| 2015 | -$20.40M | -164.7% |
| 2014 | -$7.70M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$52.25M | +24.7% | +26.6% |
| June 30, 2025 | -$71.15M | +3.5% | -10.5% |
| March 31, 2025 | -$64.39M | +4.4% | +7.3% |
| September 30, 2024 | -$69.42M | -6.1% | +5.8% |
| June 30, 2024 | -$73.71M | -7.2% | -9.4% |
| March 31, 2024 | -$67.38M | -8.3% | -3.0% |
| September 30, 2023 | -$65.43M | -11.9% | +4.8% |
| June 30, 2023 | -$68.76M | -26.8% | -10.6% |
- ROCKET PHARMACEUTICALS, INC. showed an increase of +15.2% in Operating Income compared to the prior fiscal year.
- Over the 2014–2025 period, ROCKET PHARMACEUTICALS, INC.’s operating income has declined by 2908.1% (from -$7.70 million to -$231.75 million).
- The most recent figure is from ROCKET PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: